174 related articles for article (PubMed ID: 28755795)
1. Therapeutic use of transferrin to modulate anemia and conditions of iron toxicity.
Boshuizen M; van der Ploeg K; von Bonsdorff L; Biemond BJ; Zeerleder SS; van Bruggen R; Juffermans NP
Blood Rev; 2017 Nov; 31(6):400-405. PubMed ID: 28755795
[TBL] [Abstract][Full Text] [Related]
2. Iron and oxidative stress in cardiomyopathy in thalassemia.
Berdoukas V; Coates TD; Cabantchik ZI
Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
[TBL] [Abstract][Full Text] [Related]
3. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.
Artuso I; Lidonnici MR; Altamura S; Mandelli G; Pettinato M; Muckenthaler MU; Silvestri L; Ferrari G; Camaschella C; Nai A
Blood; 2018 Nov; 132(21):2286-2297. PubMed ID: 30209118
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of beta thalassaemia.
Origa R; Galanello R
Pediatr Endocrinol Rev; 2011 Mar; 8 Suppl 2():263-70. PubMed ID: 21705976
[TBL] [Abstract][Full Text] [Related]
5. Transferrin therapy ameliorates disease in beta-thalassemic mice.
Li H; Rybicki AC; Suzuka SM; von Bonsdorff L; Breuer W; Hall CB; Cabantchik ZI; Bouhassira EE; Fabry ME; Ginzburg YZ
Nat Med; 2010 Feb; 16(2):177-82. PubMed ID: 20098432
[TBL] [Abstract][Full Text] [Related]
6. [Non-transferrin-bound iron: a promising biomarker in iron overload disorders].
Maas RP; Voets PJ; de Swart L; Swinkels DW
Ned Tijdschr Geneeskd; 2013; 157(49):A6258. PubMed ID: 24299624
[TBL] [Abstract][Full Text] [Related]
7. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the safety and efficacy of silymarin in β-thalassemia patients: a review.
Moayedi Esfahani BA; Reisi N; Mirmoghtadaei M
Hemoglobin; 2015; 39(2):75-80. PubMed ID: 25643967
[TBL] [Abstract][Full Text] [Related]
9. Role of curcuminoids in ameliorating oxidative modification in β-thalassemia/Hb E plasma proteome.
Weeraphan C; Srisomsap C; Chokchaichamnankit D; Subhasitanont P; Hatairaktham S; Charoensakdi R; Panichkul N; Siritanaratkul N; Fucharoen S; Svasti J; Kalpravidh RW
J Nutr Biochem; 2013 Mar; 24(3):578-85. PubMed ID: 22818714
[TBL] [Abstract][Full Text] [Related]
10. Integrative proteome and transcriptome analysis of extramedullary erythropoiesis and its reversal by transferrin treatment in a mouse model of beta-thalassemia.
Vallelian F; Gelderman-Fuhrmann MP; Schaer CA; Puglia M; Opitz L; Baek JH; Vostal J; Buehler PW; Schaer DJ
J Proteome Res; 2015 Feb; 14(2):1089-100. PubMed ID: 25566950
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin and transferrin metabolism in nephrotic syndrome.
Vaziri ND
Am J Kidney Dis; 2001 Jul; 38(1):1-8. PubMed ID: 11431174
[TBL] [Abstract][Full Text] [Related]
12. Iron age: novel targets for iron overload.
Casu C; Rivella S
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):216-21. PubMed ID: 25696858
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and management of iron toxicity in thalassemia.
Hershko C
Ann N Y Acad Sci; 2010 Aug; 1202():1-9. PubMed ID: 20712765
[TBL] [Abstract][Full Text] [Related]
14. The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial.
Sajadi Hezaveh Z; Azarkeivan A; Janani L; Hosseini S; Shidfar F
Complement Ther Med; 2019 Oct; 46():24-28. PubMed ID: 31519283
[TBL] [Abstract][Full Text] [Related]
15. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.
Camaschella C; Nai A
Br J Haematol; 2016 Feb; 172(4):512-23. PubMed ID: 26491866
[TBL] [Abstract][Full Text] [Related]
16. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major.
Mirlohi MS; Yaghooti H; Shirali S; Aminasnafi A; Olapour S
Ann Hematol; 2018 Apr; 97(4):679-684. PubMed ID: 29318368
[TBL] [Abstract][Full Text] [Related]
18. Treatment of β-Thalassemia/Hemoglobin E with Antioxidant Cocktails Results in Decreased Oxidative Stress, Increased Hemoglobin Concentration, and Improvement of the Hypercoagulable State.
Yanpanitch OU; Hatairaktham S; Charoensakdi R; Panichkul N; Fucharoen S; Srichairatanakool S; Siritanaratkul N; Kalpravidh RW
Oxid Med Cell Longev; 2015; 2015():537954. PubMed ID: 26078808
[TBL] [Abstract][Full Text] [Related]
19. Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis.
Matte A; De Falco L; Federti E; Cozzi A; Iolascon A; Levi S; Mohandas N; Zamo A; Bruno M; Lebouef C; Janin A; Siciliano A; Ganz T; Federico G; Carlomagno F; Mueller S; Silva I; Carbone C; Melisi D; Kim DW; Choi SY; De Franceschi L
Antioxid Redox Signal; 2018 Jan; 28(1):1-14. PubMed ID: 28793778
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of membrane alpha4beta1, alpha5beta1 integrins and transferrin receptor on erythroblasts in splenectomized patients with beta-thalassemia intermedia. Parallel assessment of serum soluble transferrin receptors levels.
Kossiva L; Paterakis G; Tassiopoulos S; Papadhimitriou SI; Voukouti E; Gligori I; Rombos Y
Ann Hematol; 2003 Sep; 82(9):579-84. PubMed ID: 12904899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
